The Pediatric infectious disease journal
-
Pediatr. Infect. Dis. J. · Feb 2010
Randomized Controlled TrialSafety and immunogenicity of trivalent inactivated influenza vaccine in infants: a randomized double-blind placebo-controlled study.
Infants less than 6 months of age are at high risk for influenza disease and influenza-related complications, but no vaccine is licensed for this population. ⋯ TIV administered to young infants beginning at 6 to 12 weeks of age is safe and immunogenic.
-
Pediatr. Infect. Dis. J. · Feb 2010
Randomized Controlled TrialClinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) l1 virus-like particle vaccine.
We describe the safety of the human papillomavirus (HPV)-6/11/16/18 vaccine using updated clinical trial data (median follow-up time of 3.6 years) and summarize up to 3 years of post-licensure surveillance. ⋯ HPV-6/11/16/18 vaccination was associated with more injection-site pain than placebo but similar incidences of systemic and serious AEs and new medical conditions potentially consistent with autoimmune phenomena. Based on review of post-licensure safety information, the benefits of vaccination to prevent the majority of genital tract precancers and cancers continue to far outweigh its risks.
-
Pediatr. Infect. Dis. J. · Feb 2010
Comment Letter Case ReportsCongenital babesiosis in a four-week-old female infant.